Payment overview · 2025
General Payments
$1,129.69
60 reported records · 16 companies
Healthcare provider profile · identity verified
Jonathan D Allred, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALCOA, TN · NPI 1134185127
Verified facts
What the public records show
CMS Open Payments records show Jonathan D Allred, MD received $1,129.69 in general payments during 2025 across 60 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $258.59 | 22.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $151.92 | 13.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.22 | 12.2% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $74.24 | 6.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $73.72 | 6.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.87 | 6.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.67 | 4.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.31 | 4.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.80 | 4.2% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $47.00 | 4.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.59 | 3.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.20 | 3.1% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $30.02 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.03 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.13 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.38 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,129.69 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $170.52 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $137.22 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $115.04 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.86 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.86 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.78 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $74.24 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $73.72 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $70.87 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.80 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.59 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $35.94 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.20 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $30.02 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 137 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
340 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1374 | 358 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1140 | 346 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1094 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 972 | 255 |
| Losartan Potassium | Losartan Potassium | 862 | 230 |
| Lisinopril | Lisinopril | 779 | 200 |
| Furosemide | Furosemide | 703 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 608 | 157 |
| Metoprolol Tartrate | Metoprolol Tartrate | 520 | 124 |
| Gabapentin | Gabapentin | 461 | 95 |
| Sertraline Hcl | Sertraline Hcl | 453 | 110 |
| Potassium Chloride | Potassium Chloride | 419 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 409 | 128 |
| Metformin Hcl | Metformin Hcl | 386 | 112 |
| Chlorthalidone | Chlorthalidone | 378 | 89 |
| Allopurinol | Allopurinol | 373 | 87 |
| Omeprazole | Omeprazole | 344 | 102 |
| Eliquis | Apixaban | 340 | 66 |
| Trazodone Hcl | Trazodone Hcl | 318 | 85 |
| Famotidine | Famotidine | 307 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 105 |
| Metformin Hcl Er | Metformin Hcl | 297 | 87 |
| Buspirone Hcl | Buspirone Hcl | 292 | 73 |
| Prednisone | Prednisone | 291 | 219 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 74 |
| Ezetimibe | Ezetimibe | 231 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 223 | 59 |
| Glimepiride | Glimepiride | 208 | 54 |
| Cefdinir | Cefdinir | 202 | 162 |
| Carvedilol | Carvedilol | 193 | 50 |
| Montelukast Sodium | Montelukast Sodium | 189 | 50 |
| Donepezil Hcl | Donepezil Hcl | 186 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 178 | 72 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 50 |
| Meloxicam | Meloxicam | 172 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 165 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 160 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 38 |
| Pregabalin | Pregabalin | 152 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 38 |
| Jardiance | Empagliflozin | 145 | 47 |
| Fenofibrate | Fenofibrate Nanocrystallized | 143 | 37 |
| Enalapril Maleate | Enalapril Maleate | 140 | 42 |
| Levofloxacin | Levofloxacin | 138 | 107 |
| Farxiga | Dapagliflozin Propanediol | 137 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 135 | 35 |
| Tramadol Hcl | Tramadol Hcl | 133 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 53 |
| Spironolactone | Spironolactone | 127 | 29 |
| Glipizide | Glipizide | 126 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 122 | 23 |
| Ibuprofen | Ibuprofen | 122 | 46 |
| Simvastatin | Simvastatin | 121 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 117 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 110 | 95 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 28 |
| Tradjenta | Linagliptin | 106 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 40 |
| Mounjaro | Tirzepatide | 104 | 28 |
| Naproxen | Naproxen | 104 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 102 | 36 |
| Cefuroxime | Cefuroxime Axetil | 101 | 96 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 22 |
| Ozempic | Semaglutide | 100 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 97 | 20 |
| Meclizine Hcl | Meclizine Hcl | 95 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 18 |
| Finasteride | Finasteride | 94 | 25 |
| Xarelto | Rivaroxaban | 93 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 85 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 29 |
| Verapamil Er | Verapamil Hcl | 83 | 13 |
| Levetiracetam | Levetiracetam | 79 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 29 |
| Alprazolam | Alprazolam | 74 | 13 |
| Warfarin Sodium | Warfarin Sodium | 72 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 21 |
| Metformin Er Gastric | Metformin Hcl | 70 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 57 |
| Febuxostat | Febuxostat | 68 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 14 |
| Celecoxib | Celecoxib | 63 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | 15 |
| Fluconazole | Fluconazole | 60 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 23 |
| Linzess | Linaclotide | 58 | 20 |
| Novolog Flexpen | Insulin Aspart | 58 | 20 |
| Synthroid | Levothyroxine Sodium | 58 | 18 |
| Alendronate Sodium | Alendronate Sodium | 57 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 57 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 27 |
| Atenolol | Atenolol | 55 | 15 |
| Glipizide Er | Glipizide | 55 | 17 |
| Benazepril Hcl | Benazepril Hcl | 54 | 13 |
| Cephalexin | Cephalexin | 54 | 42 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 51 | 13 |
| Mupirocin | Mupirocin | 51 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 11 |
| Carbamazepine | Carbamazepine | 50 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 50 | 14 |
| Clonazepam | Clonazepam | 49 | 13 |
| Mirtazapine | Mirtazapine | 49 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 48 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 14 |
| Topiramate | Topiramate | 46 | suppressed |
| Lubiprostone | Lubiprostone | 45 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 44 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Lovastatin | Lovastatin | 43 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 33 |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Nystatin | Nystatin | 41 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 11 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 39 | 12 |
| Estradiol | Estradiol | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 31 |
| Amoxicillin | Amoxicillin | 35 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 29 |
| Prasugrel Hcl | Prasugrel Hcl | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Metolazone | Metolazone | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 11 |
| Temazepam | Temazepam | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 29 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 11 |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Torsemide | Torsemide | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Famciclovir | Famciclovir | 17 | 13 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Colchicine | Colchicine | 16 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,129.69 · 60 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, CAPLYTA, CREON, Cologuard Collection Kit, ENTRESTO, FARXIGA, GVOKE HYPOPEN, INSPIRE, JARDIANCE, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VIBERZI, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error